

# Endometriosis: Market Research Report

<https://marketpublishers.com/r/EF8E7253A21EN.html>

Date: January 2019

Pages: 181

Price: US\$ 5,600.00 (Single User License)

ID: EF8E7253A21EN

## Abstracts

This report analyzes the worldwide markets for Endometriosis in US\$ Million.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs. The report profiles 38 companies including many key and niche players such as -

AbbVie Inc.

Astellas Pharma Inc.

AstraZeneca Plc

Bayer AG

Debiopharm Group

Evotec AG

## Contents

### I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations  
Disclaimers  
Data Interpretation & Reporting Level  
Quantitative Techniques & Analytics  
Product Definitions and Scope of Study

### II. EXECUTIVE SUMMARY

#### 1. INDUSTRY OVERVIEW

Endometriosis: An Introductory Prelude  
Endometriosis Facts in a Nutshell  
Poor Efficacy & Safety Profiles of Existing Drugs Lead to Unmet Medical Needs  
Key Endometriosis Drugs on the Market

**Table 1.** Leading Endometriosis Drugs on the Market (2017E): Percentage Breakdown of Revenues for Depo-Provera, Lupron, Visanne, Zoladex and Others (includes corresponding Graph/Chart)

The Pipeline Review  
Key Endometriosis Drugs in the Pipeline: 2017  
Steady Growth Expected Over the Next Few Years  
Emerging Treatment for Endometriosis & Endometrial Cancer  
Global Awareness Campaigns and Efforts  
Uptrend in Healthcare Expenditure Creates Substantial Opportunities

**Table 2.** Healthcare Spending as % of GDP by Geographic Region (2016) (includes corresponding Graph/Chart)

**Table 3.** Per Capita Healthcare Spending (in \$) in Select Developed Countries for the Year 2016 (includes corresponding Graph/Chart)

Developed Regions Remain Primary Revenue Contributors

**Table 4.** Developed Regions Account for over 90% Share of World Endometriosis Drugs Market: Percentage Breakdown of Value Sales for Developed Regions and Developing Regions (2017E & 2022P) (includes corresponding Graph/Chart)

Developing Regions Exhibit Immense Growth Potential  
Stable Economic Scenario to Augment Market Prospects

**Table 5.** World Real GDP Growth Rates in % (2016-2018P): Breakdown by Country/Region (includes corresponding Graph/Chart)

## **2. ENDOMETRIOSIS & ITS TREATMENT – AN OVERVIEW**

Introduction

Occurrence of Endometriosis in Women

Causes and Symptoms

Causes

Estrogen Theory

Müllerianosis Theory

Retrograde Menstruation Theory

Coelomic Metaplasia Theory

Hereditary Factors

Environmental Factors

Dioxin Behavior in the Body

Birth Defects

Other Causes

Symptoms of Endometriosis

Reasons for Pain due to Endometriosis

Endometriosis and Infertility

Kinds of Endometriosis

Reproductive Area Endometriosis

Uterosacral/Presacral Nerve Endometriosis

Cul-de-Sac ('Pouch of Douglas') Endometriosis

Gastrointestinal Endometriosis

Pleural (lung/chest cavity/diaphragmatic) Endometriosis

Urinary Tract (kidneys, ureters, bladder and urethra) Endometriosis

Skin Endometriosis

Sciatic Endometriosis  
Stages of Endometriosis  
Diagnosis of Endometriosis  
Major Diagnostic Techniques  
Pelvic Exam  
Laparoscopy  
Other Diagnostic Procedures  
A New Non-invasive Test for the Diagnosis of Endometriosis  
Endometriosis Markers  
Counseling of patients  
Recurrence of Endometriosis  
Endometriosis & Infertility  
Miscarriage  
Endometriosis & Thyroid Autoimmunity  
Relationship between Endometriosis and Autoimmune Disease  
Endometriosis & Cancer  
Associations & Research Centers  
The Endometriosis Association  
Endometriosis Research Center

### **3. TREATMENT OF ENDOMETRIOSIS**

Endometriosis & Available Treatment Options  
Endometriosis Treatment Mechanisms: In a Nutshell  
I. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)  
II. Hormonal Therapy  
Gonadotropin Releasing Hormone (Gnrh) Agonists  
Select Major GnRH-Agonists for Endometriosis Treatment  
Lupron, Zoladex and Synarel – The Major Drugs  
AbbVie's Lupron (Leuprorelin)  
AstraZeneca's Zoladex (Goserelin)  
Pfizer's Synarel (Nafarelin Acetate)  
Add-back Medication  
Progestogens  
Select Major Progestins for Endometriosis Treatment  
Combined Oral Contraceptive Pill  
Danazol and Other Suppressive Steroids  
Chinese Herbs – More Effective than Danazol or Gestrinone  
Aromatase Inhibitors

III. Non-hormonal Therapy  
Anti-Angiogenic Agents  
Selective COX-2 Inhibitors  
TNF-Alpha Inhibitors  
IV. Surgical Techniques  
V. Complementary Therapies  
Long-term Approach to Pain  
Lifestyle Modifications  
Chinese Herbs  
Treatment for Endometriosis-related Infertility  
Hormonal Treatment  
Minimal to Mild Endometriosis  
Moderate-Severe Endometriosis  
Surgical Treatment  
Minimal-Mild Endometriosis  
Moderate-Severe Endometriosis  
Treatment for Ovarian Endometriosis  
Surgical Vs. Medicinal Interventions  
Medicinal Interventions  
Advantages  
Disadvantages  
Surgery  
Advantages  
Disadvantages  
In-vitro Fertilization  
Other Treatment

#### **4. SELECT CLINICAL TRIALS/PRODUCT INNOVATIONS & APPROVALS**

AbbVie and Neurocrine Bag US FDA Priority Review Clearance for Elagolix  
AbbVie Announces Results from Replicate Phase 3 Extension Studies for Elagolix  
Bayer Commences Enrolling Patients for Phase III Program to Study Vilaprisan's Efficacy in Treating Symptomatic UF  
ObsEva to Commence Phase 2b EDELWEISS Clinical Trial of OBE2109  
Repros Keeps Proellex Development Program on Partial Clinical Hold of FDA  
Aeterna Zentaris Halts Development of Zoptrex  
Evotec and Bayer's Endometriosis Alliance Portfolio Advances into Phase I Clinical Development  
ObsEva Commences Phase 3 Clinical Program to Evaluate OBE2109 to Treat UF

Myovant Achieves Positive Phase 3 Study Results for Relugolix in Treating UF  
Myovant Commences Phase 3 Program of Relugolix for Treating Endometriosis-  
Associated Pain  
Repros Therapeutics' Achieves Positive Results from Proellex Phase II Study  
ValiRx Bags European Patent for VAL201  
Virexxa Receives FDA Clearance to Proceed to Phase II  
OBE2109 by ObsEva Receives IND Clearance  
Galena Biopharma Presents Phase 1/2a Data on Endometrial Cancer Immunotherapies  
AbbVie and Neurocrine Report Positive Phase 3 Trial Data of Elagolix  
ValiRx Plc to Begin Endometriosis Clinical Research with its VAL201  
Aurobindo Pharma Receives FDA Approval to Market Tablets for Endometriosis  
Treatment  
Lumenis to Introduce UltraPulse DUO CO2 laser system and FemTouch Solution  
Bayer Launches Phase II Trials of vilaprisan for Endometriosis Treatment  
Nippon Shinyaku Conducts Phase I Evaluation of NS 580 for Endometriosis Therapy  
Teleflex to Showcase its Surgical Solutions for Endometriosis  
ValiRx Plc Receives Patent Grant for VAL201

## **5. RECENT INDUSTRY ACTIVITY**

AstraZeneca Bags Commercial Rights to Zoladex  
Astellas Pharma to Acquire Ogeda  
Roivant Establishes New Global Headquarters in Basel  
Takeda and Roivant Partner to Form Myovant  
Evotec-Bayer Collaboration Reaches Important Clinical Milestones for Endometriosis  
Therapy  
ObsEva and Kissei Pharmaceutical Enter Into Collaboration Agreement for KLH-2109

## **6. FOCUS ON SELECT GLOBAL PLAYERS**

AbbVie Inc. (USA)  
Astellas Pharma Inc. (Japan)  
AstraZeneca Plc (UK)  
Bayer AG (Germany)  
Debiopharm Group (Switzerland)  
Evotec AG (Germany)  
Kissei Pharmaceutical Co., Ltd. (Japan)  
Neurocrine Biosciences, Inc. (USA)  
ObsEva SA (Switzerland)

Pfizer, Inc. (USA)  
Repros Therapeutics, Inc. (USA)  
Roivant Sciences GmbH (Switzerland)  
Takeda Pharmaceutical Company Limited (Japan)  
ValiRx plc (UK)

## 7. GLOBAL MARKET PERSPECTIVE

**Table 6.** World Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 7.** World Historic Review for Endometriosis Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 8.** World 14-Year Perspective for Endometriosis Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2009, 2017 and 2022 (includes corresponding Graph/Chart)

## III. MARKET

### 1. THE UNITED STATES

#### A. Market Analysis

Largest Market for Endometriosis Drugs

Endometriosis Associations Increase Awareness

Newer Diagnostic Methods Yet to Expand Across the Country

Key Endometriosis Drugs on the Market

Product Launches/Clinical Trials

Strategic Corporate Developments

Key Players

#### B. Market Analytics

**Table 9.** The US Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 10.** The US Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

## **2. CANADA**

A. Market Analysis

Product Launch

Key Players

B. Market Analytics

**Table 11.** Canadian Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 12.** Canadian Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

## **3. JAPAN**

A. Market Analysis

Clinical Trial

Key Players

B. Market Analytics

**Table 13.** Japanese Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 14.** Japanese Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)



## 4. EUROPE

### Market Analysis

**Table 15.** European Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region/Country - France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 16.** European Historic Review for Endometriosis Drugs by Geographic Region/ Country - France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 17.** European 14-Year Perspective for Endometriosis Drugs by Geographic Region/ Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of European Markets for Years 2009, 2017 and 2022 (includes corresponding Graph/Chart)

### 4A. FRANCE

#### A. Market Analysis

Programmes to Maintain Endometriosis Database

#### B. Market Analytics

**Table 18.** French Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 19.** French Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

### 4B. GERMANY

#### A. Market Analysis

Clinical Trials

Strategic Corporate Development

Key Players

B. Market Analytics

**Table 20.** German Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 21.** German Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

#### **4C. ITALY**

Market Analysis

**Table 22.** Italian Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 23.** Italian Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

#### **4D. THE UNITED KINGDOM**

A. Market Analysis

Product Launches/Clinical Trials

Key Players

B. Market Analytics

**Table 24.** The UK Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 25.** The UK Historic Review for Endometriosis Drugs Analyzed with Annual Sales

Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

#### **4E. SPAIN**

Market Analysis

**Table 26.** Spanish Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 27.** Spanish Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

#### **4F. REST OF EUROPE**

A. Market Analysis

Product Launches/Clinical Trials

Strategic Corporate Developments

Key Players

B. Market Analytics

**Table 28.** Rest of Europe Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 29.** Rest of Europe Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

#### **5. ASIA-PACIFIC**

A. Market Analysis

The Rapidly Growing Market

Endometriosis Therapeutics in Australia

B. Market Analytics

**Table 30.** Asia-Pacific Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 31.** Asia-Pacific Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

## 6. REST OF WORLD

A. Market Analysis

Product Launch

B. Market Analytics

**Table 32.** Rest of World Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 33.** Rest of World Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

## IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 38 (including Divisions/Subsidiaries - 40)

The United States (11)

Canada (3)

Japan (6)

Europe (15)

France (1)

Germany (3)

The United Kingdom (2)

Rest of Europe (9)

Asia-Pacific (Excluding Japan) (3)

Middle East (1)

Latin America (1)

## I would like to order

Product name: Endometriosis: Market Research Report

Product link: <https://marketpublishers.com/r/EF8E7253A21EN.html>

Price: US\$ 5,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EF8E7253A21EN.html>